Perspektiven der Chemotherapie urologischer Tumoren

  • D. K. Hossfeld
Conference paper
Part of the Verhandlungsbericht der Deutschen Gesellschaft für Urologie book series (VBDGUROLOGIE, volume 34)

Zusammenfassung

Drei Tumorerkrankungen werden in diesem Referat besprochen, die beispielhaft das gesamte Spektrum der derzeitigen Ergebnisse der Chemotherapie maligner Erkrankungen widerspiegeln, nämlich die Möglichkeit der Kuration von Patienten mit metastasiertem Hodenkarzinom, die der Palliation bei Patienten mit Harnblasenkarzinom und die Frustration bei Patienten mit metastasiertem Nierenkarzinom.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Einhorn LA, Williams SD (1980) Chemotherapy of disseminated testicular cancer. A random prospective study. Cancer 46:1339–1344.PubMedCrossRefGoogle Scholar
  2. 2.
    Vugrin D, Herr HW, Whitmore WF Jr, Sogani PC, Golbey RB (1981) VAB-6 combination chemotherapy in disseminated cancer of the testis. Ann Internal Med 95:59–61.Google Scholar
  3. 3.
    Scheulen ME, Higi M, Schilcher RB, Meier CR, Seeber S, Schmidt CG (1980) Sequentiell alternierende Chemotherapy nicht-seminomatöser Hodentumoren mit Velbe/Bleomycin und Adriamycin/Cisplatin. I. Ergebnisse einer randomisierten Studie bei 71 Patienten mit pulmonaler Metastasierung (Stadium IV). Klin Wschr 58:811–821.PubMedCrossRefGoogle Scholar
  4. 4.
    Schmoll HJ (1982) The role of ifosfamide (IPP) in testicular cancer. Proc 13 th Int Cancer Congr, Seattle 1982, p 626.Google Scholar
  5. 5.
    Einhorn LH, Williams SD, Troner M, Birch R, Greco FA (1981) The role of maintenance therapy in disseminated testicular cancer. New Engl J Med 305:727–731.PubMedCrossRefGoogle Scholar
  6. 6.
    Donohue JP, Einhorn LH, Williams SD (1980) Cytoreductive surgery for metastatic testis cancer: Considerations of timing and extent. J Urol 123:876–880.PubMedGoogle Scholar
  7. 7.
    Seeber S (1982) Current concepts in the management of early and late testicular cancer. Proc 13 th Int Cancer Congr, Seattle 1982.Google Scholar
  8. 8.
    Blachley JD, Hill JB (1981) Renal and electrolyte disturbances associated with cisplatin. Ann Internal Med 95:628–632.Google Scholar
  9. 9.
    Vogelzang NJ, Bosl GJ, Johnson K, Kennedy BJ (1981) Raynaud’s phenomenon: A common toxicity after combination chemotherapy for testicular cancer. Ann Internal Med 95:288–292.Google Scholar
  10. 10.
    Peckham MJ, Barrett A, Husband JE, Hendry WF (1982) Orchidectomy alone in testicular stage I non-seminomatous germ-cell tumours. Lancet II:678–680.CrossRefGoogle Scholar
  11. 11.
    Fossa SD, Wik B, Lien HH (1982) Phase II study of 4’-Epidoxorubicin in metastatic renal cancer. Cancer Treat Rep 66:1219–1221.PubMedGoogle Scholar
  12. 12.
    Taylor SA, von Hoff DD (1982) Phase II trial of dihydroxyanthracenedione (DHAD) in advanced renal cell carcinoma. A swog study. Proc Am Soc Clin Oncol 1:118.Google Scholar
  13. 13.
    Fuks JZ, van Echo DA, Aisner J, Kravitz S, Wiernik PH (1980) A phase II trial of 4’-(9-acridinylamino)-methanesul-fon-m-anisidide (AMSA) in patients with renal cell carcinoma of the lung (SCCL). Proc Am Ass Cancer Res and Am Soc Clin Oncol 21:477.Google Scholar
  14. 14.
    Merrin CE (1979) Treatment of genitourinary tumors with cis-dichlorodiammineplatinum (II): Experience in 250 patients. Cancer Treat Rep 63:1579–1584.PubMedGoogle Scholar
  15. 15.
    Stolbach LL, Begg CB, Hall T, Horton J (1981) Treatment of renal carcinoma: A phase III randomized trial of oral medrodyprogesterone (provera), hydroxyurea, and nafoxidine. Cancer Treat Rep 65:689–692.PubMedGoogle Scholar
  16. 16.
    Todd RF III, Garaick MB, Canellos GP, Richie JP, Gittes RF, Mayer RJ, Skarin AT (1981) Phase I-II trial of methyl-GAG in the treatment of patients with metastatic renal adenocarcinoma. Cancer Treat Rep 65:17–20.PubMedGoogle Scholar
  17. 17.
    Baumgartner G, Heinz R, Arbes H, Lenzhofer R, Pridun N, Schüller J (1980) Methotrex-ate-citrovorum factor used alone and in combination chemotherapy for advanced hypernephromas. Cancer Treat Rep 64:41–45.PubMedGoogle Scholar
  18. 18.
    Zeffren J, Yagoda A, Kelsen D, Winn R (1980) Phase I trial of a 5-day infusion of vinblastine (VLB). Proc Am Ass Cancer Res and Am Soc Clin Oncol 21:178.Google Scholar
  19. 19.
    Al-Sarraf M, Eyre H, Bonnet J, Saiki J, Gagliano R, Pugh R, Lehane D, Dixon D, Bottomley R (1981) A study of tamoxifen in metastatic renal cell carcinoma and the influence of certain prognostic factors: A Southwest Oncology Group Study. Cancer Treat Rep 65:447–451.PubMedGoogle Scholar
  20. 20.
    Papac R, Luikhart S, Kirkwood J (1980) High dose tamoxifen in patients with advanced renal cell cancer and malignant melanoma. Proc Am Ass Cancer Res and Am Soc Clin Oncol 21:358.Google Scholar
  21. 21.
    Benedetto P, Yagoda A, Watson RC, Sogani P, Neri RO, Pertschuk LP, Fishman J, Bradlow JL (1981) Phase II trial of flutamide in hypernephroma correlation with hormone receptor sites. Proc Am Ass Cancer Res and Am Soc Clin Oncol 22:466.Google Scholar
  22. 22.
    Smith PH (1981) Chemotherapy of bladder cancer: A review. Cancer Treat Rep 65:173.Google Scholar
  23. 23.
    Herr HW (1980) Cis-diamminedichloride platinum II in the treatment of advanced bladder cancer. J Urol 123:853–855.PubMedGoogle Scholar
  24. 24.
    Kedia KR, Gibbons C, Persky L (1981) The management of advanced bladder carcinoma. J Urol 125:655–658.PubMedGoogle Scholar
  25. 25.
    Troner MB, Hemstreet GP (1981) Cyclo phosphamide, doxorubicin, and cisplatin (CAP) in the treatment of urothelial malignancy: A pilot study of the Southeastern Cancer Study Group. Cancer Treat Rep 65:29–32.PubMedGoogle Scholar
  26. 26.
    Baker LH, Al-Sarraf M, Opipari M (1980) Combination chemotherapy (CAP) in patients with advanced urothelial cancers. Proc Am Ass Cancer Res and Am Soc Clin Oncol 21:429.Google Scholar
  27. 27.
    Einstein A, Soloway M, Corder M, Bonney W, Coombs J (1981) Diamminedichloroplatinum (DDP) VS. DDP plus cyclophosphamide (CY) for metastatic bladder carcinoma. Proc Am Ass Cancer Res and Am Soc Clin Oncol 22:461.Google Scholar
  28. 28.
    Blumenreich MS, Needles B, Yagoda A, Sogani P, Grabstald H, Whitmore WF Jr (1982) Intravesical cisplatin for superficial bladder tumors. Cancer 50:863–865.PubMedCrossRefGoogle Scholar
  29. 29.
    Horn Y, Eidelman A, Walach N, Ilian M, Markowitz A (1982) Treatment of superficial bladder tumors in a controlled trial with adriamycin versus thio-tepa. Proc 13 th Int Cancer Congr, Seattle 1982, p 619.Google Scholar
  30. 30.
    Issell BF, DeFuria MD, Fandrich SE (1981) Topical mitomycin C (MMC) in thiotepa refractory non-invasive bladder cancer. Proc Am Ass Cancer Res and Am Soc Clin Oncol 22:464.Google Scholar
  31. 31.
    Wajsman Z, Lee F, Mac Donald S, Sandberg AA, Pontes JE (1982) Absorption studies of mitomycin C (MMC) during intravesical treatment of superficial bladder cancer. Proc Am Soc Clin Oncol 1:116.Google Scholar
  32. 32.
    Hall RR, Herring DW, McGill AC, Gibb I (1981) Oral methotrexate therapy for multiple superficial bladder carcinomata. Cancer Treat Rep 65:175–178.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1983

Authors and Affiliations

  • D. K. Hossfeld
    • 1
  1. 1.Med. Klinik, Abt. für Onkologie und HämatologieUniversitäts-Krankenhaus EppendorfHamburg 20Deutschland

Personalised recommendations